SUPERNUS PHARMACEUTICALS, INC. Repayments of Convertible Debt
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-03-02
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2024-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2024-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2023-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2023-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2025 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2023 was $402.50M.
- SUPERNUS PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2022 was $0.00.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $402.50M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $402.50M 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $402.50M 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $0.00 derived: sum of 3 quarters · filed 2017-03-16 | $1.00K 10-K · filed 2017-03-16 |
| 2014-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $0.00 derived: sum of 2 quarters · filed 2017-01-20 | $1.00K 10-Q/A · filed 2017-01-20 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $1.00K 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $1.00K 10-Q · filed 2015-05-06 | |||
| 2013-12-31 | $1.73M 10-K/A · filed 2017-01-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |